Scope of this summary
Adults with hepatic steatosis on imaging, unexplained liver-chemistry elevation or metabolic risk suggesting metabolic dysfunction-associated steatotic liver disease. The core 2023 AASLD guidance used NAFLD/NASH terminology; the current AASLD portal adds MASLD nomenclature and therapy updates. Pediatric disease, pregnancy and decompensated cirrhosis require specialist pathways.
The Bottom Line
- Evaluate alcohol exposure, metabolic comorbidity, medicines and competing liver diseases rather than assuming every steatotic liver is MASLD; normal aminotransferases do not exclude advanced fibrosis.
- Use a primary fibrosis assessment such as FIB-4 in adults with suspected disease, but do not rely on FIB-4 in acutely ill patients and interpret age-related limitations explicitly.
- When FIB-4 is at least 1.3, proceed to a secondary assessment—preferably vibration-controlled transient elastography or the Enhanced Liver Fibrosis test—or refer for further risk stratification; in adults over 65 years use the source-defined higher threshold.
- Target sustained weight loss, physical activity and cardiometabolic risk. AASLD associates roughly 3%–5% weight loss with steatosis improvement and usually more than 10% with greater likelihood of improving MASH and fibrosis.
- Manage cardiovascular risk aggressively and use current AASLD and FDA criteria for any liver-directed therapy; do not infer an indication for semaglutide, resmetirom or another medicine from steatosis alone.
Practical clinical workflow
1
Confirm the imaging or laboratory finding, quantify alcohol and review diabetes, obesity, dyslipidemia, sleep apnea, family history, medicines, viral hepatitis and physical signs of advanced liver disease.
2
Calculate FIB-4 when clinically appropriate. Repeat low-risk assessment at an interval matched to diabetes and metabolic risk rather than treating a single low value as lifelong reassurance.
3
Obtain elastography or an accepted blood-based secondary test after an indeterminate or elevated first-line result; refer directly for persistent aminotransferase elevation, high-risk noninvasive tests or suspected cirrhosis.
4
Agree a culturally and practically sustainable nutrition, activity and weight plan; optimize diabetes, blood pressure, lipids, obstructive sleep apnea and tobacco treatment with the relevant clinicians.
5
When cirrhosis is identified or strongly suspected, initiate hepatology-led complication assessment, hepatocellular-carcinoma surveillance and variceal risk management without waiting for symptoms.
Safety boundaries and escalation
- Jaundice, ascites, encephalopathy, gastrointestinal bleeding, severe coagulopathy or acute marked liver injury requires urgent assessment outside a routine MASLD pathway.
- FIB-4 can be misleading in acute illness, in younger adults and at older ages; discordant noninvasive tests require specialist interpretation rather than automatic reassurance or labeling.
- Do not prescribe a liver-directed therapy without checking the current FDA indication, fibrosis stage, contraindications, drug interactions and monitoring requirements.
- Statins are used for cardiovascular-risk reduction in appropriately selected patients with compensated liver disease; do not withhold needed prevention solely because MASLD is present, while evaluating true drug-induced injury normally.
Localization
US practice now uses MASLD/MASH terminology while much of the pivotal AASLD document uses NAFLD/NASH. Current AASLD therapy updates, FDA labeling and US hepatology access control implementation.
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- American Association for the Study of Liver DiseasesAASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver diseaseDOI 10.1097/HEP.0000000000000323 · 2023 guidance; MASLD nomenclature update and later therapy updates must be read alongside it · published 2023-05-01 · accessed 2026-08-20view source
- American Association for the Study of Liver DiseasesClinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Diseasecurrent AASLD portal linking nomenclature, resmetirom and semaglutide updates · published 2023-01-01 · updated 2025-11-01 · accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.